Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Non-Small-Cell Lung
Interventions: Canakinumab, Docetaxel, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more

Conditions: HIV Infections
Interventions: DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine, Placebo for DNA-HIV-PT123 vaccine, Placebo for NYVAC-HIV-PT1 vaccine, Placebo for NYVAC-HIV-PT4 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more

Conditions: Pre-Diabetic
Interventions: Calcitriol capsules, Oral Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 45 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma
Interventions: Bevacizumab, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 872
States / cities: Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 529 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 56
States / cities: Tucson, Arizona • Anaheim, California • Canoga Park, California + 46 more

Conditions: Hepatitis C
Interventions: 200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Reduction of Hypertrophic Skin Scarring
Interventions: PF-06473871; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 36
States / cities: Irvine, California • La Jolla, California • Walnut Creek, California + 20 more

Conditions: Healthy
Interventions: Tolperisone Hydrochloride, Cyclobenzaprine Hydrochloride 10 MG, Placebo; Drug · Other
Lead sponsor: Neurana Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Long Beach, California • Berlin, New Jersey

Conditions: Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
Interventions: BX004-A, Placebo; Drug
Lead sponsor: BiomX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 18
States / cities: Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 15 more

Conditions: Psoriasis
Interventions: Placebo, 50 mg etanercept, 80 mg ixekizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 41
States / cities: Anaheim, California • Bakersfield, California • Bell Gardens, California + 38 more

Conditions: Gastric Bypass, Parathyroid Hormone
Interventions: Paricalcitol, Cholecalciferol, Placebo; Drug
Lead sponsor: Kerstyn C. Zalesin, M.D.; Other
Eligibility: 18 Years to 100 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Autoimmune Hepatitis
Interventions: VAY736, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 4
States / cities: Coronado, California • Rialto, California • Sacramento, California + 1 more

Conditions: Adenocarcinoma of the Prostate, Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer
Interventions: diindolylmethane, placebo, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Delirium, Sleep
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years and older
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: CX157, Placebo; Drug · Other
Lead sponsor: CeNeRx BioPharma Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: HIV-1 Infected Adults With Chronic HIV-1 Infection
Interventions: Arm A: Poly-ICLC, Arm B: Normal Saline; Drug
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumors
Interventions: E7080, Comparator Drug, Comparator Drug: Sorafenib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Torrance, California • Chicago, Illinois • Detroit, Michigan

Conditions: Smoking Cessation, Nicotine Dependence
Interventions: Nicotine Replacement Treatment (NRT), varenicline, Behavioral counseling for smoking cessation; Drug · Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Dentin Sensitivity
Interventions: Experimental Oral Rinse 1, Experimental Oral Rinse 2, Placebo Oral Rinse, Fluoride toothpaste; Device · Other · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Creatine Monohydrate; Drug
Lead sponsor: The Avicena Group; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 8
States / cities: San Francisco, California • Kansas City, Kansas • Albuquerque, New Mexico + 5 more

Conditions: Immunoglobulin A (IgA) Nephropathy
Interventions: Felzartamab, Placebo; Drug · Other
Lead sponsor: HI-Bio, A Biogen Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Oxnard, California • Vacaville, California • Rochester, Minnesota + 1 more

Conditions: Arthritis, Reactive, Reiter Disease
Interventions: Doxycycline and Rifampin, Azithromycin and Rifampin, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Tampa, Florida • New Orleans, Louisiana

Conditions: Gastroesophageal Reflux, Apnea, Bradycardia
Interventions: Erythromycin, Multi-channel intra-luminal impedance (MII) pH monitoring, Placebo (D5W); Drug · Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Days and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hyperhidrosis
Interventions: Ulthera System Treatment, Sham treatment; Drug
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Aventura, Florida

Search by objective public record fields.

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults

Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

Effects of Tolperisone on Measures of Drowsiness and Cognitive Function

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer

Investigation of Sleep in the Intensive Care Unit

Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers

Enhancement by Poly-ICLC During HIV-1 Infection

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Varenicline and Motivational Advice for Smokers With Substance Use Disorders

A Study in Dentinal Hypersensitivity (DH) Participants to Assess the Efficacy of an Occluding Dentifrice.

Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria

Study of Erythromycin in GER-Associated Apnea of the Newborn

Feasibility Study: Safety and Efficacy of the Ulthera® System for Treatment of Axillary Hyperhidrosis